Olena Barbash
Overview
Explore the profile of Olena Barbash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah V, Giotopoulos G, Osaki H, Meyerhofer M, Meduri E, Gallego-Crespo A, et al.
Blood
. 2024 Dec;
145(7):748-764.
PMID: 39651888
Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves...
2.
Zhang H, Rutkowska A, Gonzalez-Martin A, Mirza M, Monk B, Vergote I, et al.
Cancer Res Commun
. 2024 Dec;
5(1):178-186.
PMID: 39636225
The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are...
3.
Watts J, Minden M, Bachiashvili K, Brunner A, Abedin S, Crossman T, et al.
Ther Adv Hematol
. 2024 Sep;
15:20406207241275376.
PMID: 39290981
Background: GSK3326595 is a potent, selective, reversible protein arginine methyltransferase 5 (PRMT5) inhibitor under investigation for treatment of myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML)....
4.
Cescon D, Hilton J, Morales Murilo S, Layman R, Pluard T, Yeo B, et al.
Clin Cancer Res
. 2023 Nov;
30(2):334-343.
PMID: 37992310
Purpose: Endocrine-based therapy is the initial primary treatment option for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). However, patients eventually experience disease progression...
5.
Dawson M, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, et al.
Clin Cancer Res
. 2022 Nov;
29(4):711-722.
PMID: 36350312
Purpose: Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment...
6.
Erazo T, Evans C, Zakheim D, Chu E, Refermat A, Asgari Z, et al.
Nat Commun
. 2022 Sep;
13(1):5676.
PMID: 36167829
To identify drivers of sensitivity and resistance to Protein Arginine Methyltransferase 5 (PRMT5) inhibition, we perform a genome-wide CRISPR/Cas9 screen. We identify TP53 and RNA-binding protein MUSASHI2 (MSI2) as the...
7.
Stewart M, Merino Vega D, Arend R, Baden J, Barbash O, Beaubier N, et al.
Oncologist
. 2022 Mar;
27(3):167-174.
PMID: 35274707
Background: Homologous recombination deficiency (HRD) is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-strand breaks using the homologous recombination repair (HRR) pathway....
8.
Fedoriw A, Shi L, OBrien S, Smitheman K, Wang Y, Hou J, et al.
Cancer Immunol Res
. 2022 Feb;
10(4):420-436.
PMID: 35181787
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric...
9.
Zappacosta F, Wagner C, Della Pietra 3rd A, Gerhart S, Keenan K, Korenchuck S, et al.
Mol Cell Proteomics
. 2021 Mar;
20:100067.
PMID: 33775892
Histones are highly posttranslationally modified proteins that regulate gene expression by modulating chromatin structure and function. Acetylation and methylation are the most abundant histone modifications, with methylation occurring on lysine...
10.
Piha-Paul S, Hann C, French C, Cousin S, Brana I, Cassier P, et al.
JNCI Cancer Spectr
. 2020 Apr;
4(2):pkz093.
PMID: 32328561
Background: Bromodomain and extra-terminal domain proteins are promising epigenetic anticancer drug targets. This first-in-human study evaluated the safety, recommended phase II dose, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the...